Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 sep 2008 - 13:42
Statutaire naam
Crucell N.V.
Titel
DSM and Crucell announce another key achievement for PER.C6® Technology; Scale up of high-titer Fed-Batch Process to 250 Liters
Bericht
Groningen/Leiden, The Netherlands; Parsippany, USA, 29 September 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6® Development Center, their joint venture in Cambridge, USA was recently scaled up to 250 liters by DSM Biologics scientists at their GMP facility in Groningen, The Netherlands. They successfully achieved 8 grams per liter for an IgG expressed by PER.C6® cells using chemically defined cell culture medium in a SUB (single-use bioreactor).
This result confirms a reliable, versatile and commercially feasible production platform to manufacture large amounts of therapeutic proteins with ease and economic affordability. Also, this latest result, using conventional fed-batch process, adds to the previous achievements of 27 grams per liter – biomass corrected – using DSM’s XD™ technology, and demonstrating a reliable performance of the PER.C6® cell line under such production conditions.
Marco Cacciuttolo, CEO and President of PERCIVIA, comments that “This new development further strengthens our commitment to modernize therapeutic protein manufacturing. The successful scale up of the high titer fed-batch process means that the PER.C6® platform can be easily and quickly implemented into commercial facilities with no retrofit requirements. We continue to be very pleased and enthused by the ease of use, the reproducibility, and the overall robustness of the platform.”
Datum laatste update: 01 september 2024